Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track
Intellia Therapeutics on Monday reported its experimental CRISPR gene-editing therapy led to a significant reduction in swelling attacks in a late-stage hereditary angioedema study.…

















